Oruka Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2012 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Oruka Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2012 to Q3 2024.
  • Oruka Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 6.57 %, a 74.6% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 6.57 +2.81 +74.6% Sep 30, 2024
Q2 2024 12.6 +8.33 +195% Jun 30, 2024
Q1 2024 5.12 +0.22 +4.5% Mar 31, 2024
Q4 2023 3.51 -2.05 -36.8% Dec 31, 2023
Q3 2023 3.76 -2.84 -43% Sep 30, 2023
Q2 2023 4.28 -2.55 -37.4% Jun 30, 2023
Q1 2023 4.89 -1.88 -27.8% Mar 31, 2023
Q4 2022 5.56 -0.77 -12.2% Dec 31, 2022
Q3 2022 6.61 +0.13 +2.01% Sep 30, 2022
Q2 2022 6.82 Jun 30, 2022
Q1 2022 6.77 Mar 31, 2022
Q4 2021 6.34 Dec 31, 2021
Q3 2021 6.47 Sep 30, 2021
Q4 2018 13.7 -3.36 -19.8% Dec 31, 2018
Q3 2018 15.6 +0.97 +6.65% Sep 30, 2018
Q2 2018 16.7 +4.75 +39.7% Jun 30, 2018
Q1 2018 17.7 +8.58 +93.8% Mar 31, 2018
Q4 2017 17 Dec 31, 2017
Q3 2017 14.6 Sep 30, 2017
Q2 2017 12 Jun 30, 2017
Q1 2017 9.15 Mar 31, 2017
Q4 2015 3.92 -2.36 -37.6% Dec 31, 2015
Q3 2015 4.64 -1.72 -27% Sep 30, 2015
Q2 2015 5.38 -0.79 -12.8% Jun 30, 2015
Q1 2015 7.23 +1.75 +31.9% Mar 31, 2015
Q4 2014 6.28 -0.44 -6.55% Dec 31, 2014
Q3 2014 6.36 +0.42 +7.07% Sep 30, 2014
Q2 2014 6.17 -1.21 -16.4% Jun 30, 2014
Q1 2014 5.49 -9.88 -64.3% Mar 31, 2014
Q4 2013 6.72 -5.83 -46.5% Dec 31, 2013
Q3 2013 5.94 -7.27 -55% Sep 30, 2013
Q2 2013 7.37 -6.17 -45.6% Jun 30, 2013
Q1 2013 15.4 +2.12 +16% Mar 31, 2013
Q4 2012 12.6 Dec 31, 2012
Q3 2012 13.2 Sep 30, 2012
Q2 2012 13.5 Jun 30, 2012
Q1 2012 13.2 Mar 31, 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.